Clinical Trials Directory

Trials / Conditions / Age-Related Maculopathy

Age-Related Maculopathy

21 registered clinical trials studyying Age-Related Maculopathy.

StatusTrialSponsorPhase
UnknownOphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases
NCT05752045
Evolucare TechnologiesN/A
TerminatedEfficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related M
NCT01577381
PfizerPhase 2
CompletedSafety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration
NCT01494805
Lions Eye Institute, Perth, Western AustraliaPhase 1 / Phase 2
Active Not RecruitingGARM II: A Study on the Genetics of Age-related Maculopathy
NCT01115387
University of California, Los Angeles—
CompletedSafety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Includin
NCT01003691
PfizerPhase 1
TerminatedSafety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascul
NCT01122511
AllerganPhase 2
CompletedSafety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AM
NCT01024998
Genzyme, a Sanofi CompanyPhase 1
CompletedLong Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation for Two More Years (LUTEGA 2)
NCT01648660
University of JenaN/A
CompletedSafety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
NCT00877032
PfizerPhase 1
CompletedSafety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VE
NCT00775411
AllerganPhase 2
CompletedA Multi-Center Study of Reading Rehabilitation in Macular Disease
NCT00746668
US Department of Veterans AffairsN/A
CompletedLong Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA
NCT00763659
University of JenaN/A
CompletedValidation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function
NCT00759044
Association for Innovation and Biomedical Research on Light and Image—
CompletedSafety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-
NCT00511706
AllerganPhase 2
CompletedReduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular
NCT00473642
Oklahoma State University Center for Health SciencesPhase 4
TerminatedStudy Evaluating Genotypes Using Lucentis
NCT00474695
University of Utah—
SuspendedSafety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rhe
NCT00460967
OccuLogixPhase 3
CompletedAnecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration
NCT00051129
Alcon ResearchPhase 3
CompletedThe Role of Macular Pigment in Patients With Age-related Macular Degeneration
NCT00494325
Insel Gruppe AG, University Hospital Bern—
CompletedMeasuring Reading Rehabilitation Outcomes
NCT00125632
US Department of Veterans AffairsN/A
CompletedIntravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degener
NCT00056823
Genentech, Inc.Phase 1 / Phase 2